Market Overview

UPDATE: Jefferies Raises PT on Merck & Co. on Positive Outlook

Share:
Related MRK
Merck's Keytruda Gets FDA Priority Review For Rare Lymphoma
3 Stocks In Focus As Biotech M&A Hopes For 2018 Rise
3 Things In Biotech You Should Learn Today: December 12, 2017 (Seeking Alpha)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Hold rating on Merck & Co. (NYSE: MRK), and raised the price target from $46.00 to $48.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Merck & Co. closed on Tuesday at $45.51.

Latest Ratings for MRK

DateFirmActionFromTo
Nov 2017Bank of AmericaReinstatesBuyBuy
Oct 2017BMO CapitalMaintainsOutperform
Oct 2017JefferiesUpgradesUnderperformHold

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (MRK)

View Comments and Join the Discussion!

Partner Center